253 related articles for article (PubMed ID: 34666314)
1. How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis.
Schaefer JK; Elshoury A; Nachar VR; Streiff MB; Lim MY
J Natl Compr Canc Netw; 2021 Oct; 19(10):1203-1210. PubMed ID: 34666314
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.
Klamroth R; Sinn M; Pollich C; Bischoff S; Lohneis A; Orlovic AM; Wisłocka L; Habbel P; de Wit M; Späth-Schwalbe E; Scholz CW; Riess H
Oncol Res Treat; 2022; 45(4):178-185. PubMed ID: 34963120
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
4. An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Cosmi B
Expert Opin Pharmacother; 2021 Apr; 22(5):583-594. PubMed ID: 33243038
[No Abstract] [Full Text] [Related]
5. [Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use].
Malka D; Girard N; Smadja DM; Chevreau C; Culine S; Lesur A; Rouzier R; Rozet F; Spano JP; Blay JY
Bull Cancer; 2023 Feb; 110(2):212-224. PubMed ID: 36494243
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs.
Schaefer JK; Li M; Wu Z; Basu T; Dorsch MP; Barnes GD; Carrier M; Griggs JJ; Sood SL
J Thromb Haemost; 2021 Jan; 19(1):212-220. PubMed ID: 33104289
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management.
Riess H; Verhamme P; Weitz JI; Young A; Bauersachs R; Beyer-Westendorf J; Crowther M; Maraveyas A
Crit Rev Oncol Hematol; 2021 Jan; 157():103125. PubMed ID: 33254037
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada.
Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ
Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism.
Chai-Adisaksopha C; Iorio A; Crowther MA; de Miguel J; Salgado E; Zdraveska M; Fernández-Capitán C; Nieto JA; Barillari G; Bertoletti L; Monreal M;
Am J Med; 2018 Apr; 131(4):430-437. PubMed ID: 29274307
[TBL] [Abstract][Full Text] [Related]
11. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
12. How I treat and prevent venous thrombotic complications in patients with lymphoma.
Schmidt RA; Lee AYY
Blood; 2022 Mar; 139(10):1489-1500. PubMed ID: 34479364
[TBL] [Abstract][Full Text] [Related]
13. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.
Martins MA; Silva TF; Fernandes CJ
Curr Oncol Rep; 2023 May; 25(5):425-432. PubMed ID: 36928825
[TBL] [Abstract][Full Text] [Related]
14. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
16. Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants.
Kim SA; Yhim HY; Bang SM
J Korean Med Sci; 2019 Feb; 34(6):e52. PubMed ID: 30787683
[TBL] [Abstract][Full Text] [Related]
17. Management of cancer-associated venous thromboembolism - a case-based practical approach.
Voigtlaender M; Langer F
Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Acute Venous Thromboembolism.
Nair S; Garza N; George M; Kaatz S
Med Clin North Am; 2020 Jul; 104(4):631-646. PubMed ID: 32505257
[TBL] [Abstract][Full Text] [Related]
19. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.
Jiménez-Fonseca P; Gallardo E; Arranz Arija F; Blanco JM; Callejo A; Lavin DC; Costa Rivas M; Mosquera J; Rodrigo A; Sánchez Morillas R; Vares Gonzaléz M; Muñoz A; Carmona-Bayonas A
Eur J Intern Med; 2022 Jun; 100():33-45. PubMed ID: 35227541
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Venous Thromboembolism in Cancer. Historical Perspective and Evolving Role of the Direct Oral Anticoagulants.
Carrier M; Soff G; Le Gal G
Cancer Treat Res; 2019; 179():103-115. PubMed ID: 31317483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
